Thus, Orai3 that has been identified as an independent prognostic marker of survival and metastasis in lung adenocarcinoma [22] can be also used as a future strategy in targeting CSCs subsets in CDDP resistant NSCLC tumors. This evidence concerns the gene ORAI3 and lung adenocarcinoma.